Merck & Co's Gefapixant Cuts Chronic Cough in Phase III
But Concerns Over Taste Side Effects
Executive Summary
New data puts Merck & Co's P2X3 receptor antagonist ahead of the field but Bellus Health's rival in the class may benefit from issues over taste alteration with gefapixant.
You may also be interested in...
Roivant's New Respiratory-Focused Vant Adds Chronic Cough Candidate To The Portfolio
Respivant will be Roivant's 13th "vant," focused on developing what was Patara Pharma's mast cell stimulator for chronic cough in patients with idiopathic pulmonary fibrosis. Former Patara CEO Bill Gerhart will lead the firm.
Merck To Get Chronic Cough P2X3 Inhibitor Candidate With Afferent Buy
A candidate for chronic cough is one of the assets Merck & Co. will get by buying P2X3 inhibitor specialist Afferent Pharmaceuticals Inc, a US-based biotech focusing on chronic pain therapies caused when certain nerves become hypersensitive.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.